Clinical Trial Update: Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) [Phase 2]

View source ↗

Summary

Phase II trial update (VISION) evaluating Tepotinib in advanced non-small cell lung cancer with MET alterations; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Tepotinib (Tepmetko) (tepotinib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-09